Zhejiang Tianyu Pharmaceutical(300702.SZ): Apatamine API passes CDE review.

15:58 07/01/2026

Tianyu Group (300702.SZ) announced that its wholly-owned subsidiary Zhejiang Jingsheng Pharmaceutical Co., Ltd. ("Jingsheng Pharmaceutical") recently passed the evaluation of abiraterone raw materials by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. Abiraterone is a non-steroidal antiandrogen used for the treatment of prostate cancer. It works by inhibiting the androgen receptor signaling pathway to slow down disease progression. It is mainly used for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC), and should be used in conjunction with castration therapy under the guidance of a doctor.

Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that its wholly-owned subsidiary Zhejiang Jingsheng Pharmaceutical Co., Ltd. ("Jingsheng Pharmaceutical") recently passed the review of abiraterone raw materials by the National Medical Products Administration's Drug Evaluation Center (CDE). Abiraterone is a non-steroidal anti-androgen drug used to treat prostate cancer by inhibiting the androgen receptor signaling pathway and delaying disease progression. It is mainly used for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC), and must be used in combination with castration therapy under the guidance of a doctor.

Teamway International Group Limited (01239) issued 39.45 million shares for subscription, raising approximately 134 million Hong Kong dollars.

Shenzhen Kangtai Biological Products (300601.SZ): Application for clinical trial of adsorbed acellular pertussis (components) combined vaccine (for adults, teenagers, and children) has been accepted.

On January 8, LIANLIAN (02598) spent HK$954,000 to repurchase 140,000 shares.

Teamway International Group Limited (01239) issued 39.45 million shares for subscription, raising approximately 134 million Hong Kong dollars.

Shenzhen Kangtai Biological Products (300601.SZ): Application for clinical trial of adsorbed acellular pertussis (components) combined vaccine (for adults, teenagers, and children) has been accepted.

On January 8, LIANLIAN (02598) spent HK$954,000 to repurchase 140,000 shares.